ReviewFrontiers in pharmacology2026
Molecular mechanisms of polysaccharide components of kidney-tonifying traditional Chinese medicine in regulating osteoporosis.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis, a prevalent systemic skeletal disorder, poses a significant health risk to the elderly population, arising from a multitude of factors that disrupt bone homeostasis. This delicate balance is primarily regulated by the dynamic interplay between osteoblasts and osteoclasts. When this equilibrium is perturbed, osteoporosis can ensue. Traditional Chinese Medicine (TCM) posits that the kidney, as the repository of vital essence, is instrumental in the production of bone marrow, which in turn confers skeletal strength. Consequently, TCM therapies that focus on kidney replenishment are frequently employed in the management of osteoporosis and other bone-related conditions. The polysaccharide metabolites of these TCM, which are designed to invigorate the kidney, exhibit a spectrum of pharmacological activities and engage multiple targets, such as Wnt and BMP-2/Smads signaling pathway activation and oxidative stress reduction. Notably, the protective and therapeutic roles of these polysaccharides in osteoporosis are mediated through distinct mechanisms and pathways. This review provides an overview of the application of the polysaccharide metabolites of kidney-tonifying TCM in the field of osteoporosis, with special emphasis on the mechanisms underlying the pharmacological effects of the various polysaccharide metabolites. It meticulously examines the precise molecular underpinnings and pathways through which these polysaccharides influence osteogenesis and osteoclastogenesis, with the aim of providing a robust foundation for future investigative endeavors and clinical applications of these polysaccharide metabolites in TCM kidney-tonifying therapies. This review summarizes preclinical evidence from animal and cell studies. However, clinical translation remains limited as most findings await validation in human trials. Moreover, this review aims to bolster the empirical evidence supporting the TCM principle that "the kidney governs the bones," thereby enriching the understanding and practical application of this ancient medical wisdom in contemporary healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.